ASH 2023 | Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, shares the findings of a longitudinal analysis which explored the impact of momelotinib on transfusion burden in patients with JAK inhibitor-naïve and -experienced myelofibrosis (MF). Using data from the Phase III SIMPLIFY-1 (NCT01969838) and MOMENTUM (NCT04173494) trials, Dr Mesa explains that patients treated with momelotinib demonstrated an anemia benefit, as well as a reduction in transfusion burden compared to both ruxolitinib and danazol. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Promedior, Incyte, Genetech, Abbvie, Samus, Celgene, Constellation, CTI BioPharma., a Sobi Company, Mays Cancer Center, NCI; Consultancy: Constellation, LaJolla Pharma, Sierra Onc, Novartis.
